Further intensification of PORT-C was investigated in a phase II trial, where it was suggested that adding panitumumab, an antibody to EGFR, might be superior to PORT-C for high risk HPV-negative HNSCC patients [45]. Here, EGFR is linked to head and neck squamous cell carcinoma.